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Pietro Scicchitanon, Pier S. Sabaq and Marco M. CicconenCardiovascular disease (CVD) accounts for more than
17 million deaths per year worldwide. It has been estimated
that the influence of lifestyle on CVD mortality amounts to
13.7% for smoking, 13.2% for poor diet, and 12% for inactive
lifestyle. These results deeply impact both the healthy
status of individuals and their skills in working. The impact
of CVD on productivity loss accounts for the 24% in total
costs for CVD management.
Mediterranean diet (MedD) can positively impact on natural
history of CVD. It is characterized by a relatively high
consumptionof inexpensiveandgenuine foodsuchas cereals,
vegetables, legumes, nuts, fish, fresh fruits, and olive oil as the
principal source of fat, low meat consumption and low-to-
moderate consumption of milk, dairy products, and wine.
Its effects on cardiovascular health are related to the
significant improvements in arterial stiffness. Peripheral
artery disease, coronary artery disease, and chronic heart
failure are all positively influenced by the MedD.
Furthermore, MedD lowers the risk of sudden cardiac death
due to arrhythmias.
The present narrative review aims to analyze the effects of
MedD on CVD.
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Cardiovascular disease (CVD) is the primary global cause
of death, responsible for more than 17 million deaths per
year.1,2 The contribution of unhealthy lifestyle to the
development of CVD in high-income and middle-income
countries is unquestionable.3,4 It has been estimated that
the impact on CVD mortality of lifestyle amounts to 13.7%
for smoking, 13.2% for poor diet, and 12% for inactive
lifestyle.5,6 Smoking, poor diet, inactive lifestyle, and
excessive alcohol consumption are responsible for almost
40% of all deaths and 80% of chronic diseases in the UnitedStates.5 Improving cardiovascular health is a strategic goal
in public health, and improving the average quality of diet
is fundamental in achieving such a therapeutic goal.1–7
The present narrative review aims to analyze the effects
of healthy Mediterranean diet (MedD) on CVD.‘Mediterranean diet’ definition and state of
the art
MedD refers to the eating habits found in some Mediter-
ranean populations (particularly Crete and southern Italy)DOI:10.2459/JCM.0000000000000573
ardiology. All rights reserved.
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Fig. 1
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Meat
Eggs
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The mediterranean diet pyramid
Daily
Milk
Vegetables
Cereals Bread
Potatoes Pasta,flour
Fruit Olive oil
Regular physical activity
200 ml/day
2 or more protions/day 3 or more protions/day 3-6 protions/day
250 g 40-60 g
Yogurt
Poultry/lean meat
2 portions/week
2-4 portions/week
Legumes
Cheese
2-4 portions/week
2-4 portions/day
3-4 portions/week
3-5 portions/week
3-6 portions/day
4-6 portions/day
The pyramid of Mediterranean diet: components and quantities for health protection.in the mid-20th century. In this area, after the Second
World War nutrition was scarce and characterized by a
relatively high consumption of inexpensive and genuine
food such as cereals, vegetables, legumes, nuts, fish, fresh
fruits, and olive oil as the principal source of fat (Fig. 1).
The consumption of meat was low, whereas the consump-
tion of milk, dairy products and wine was low–moderate
(Fig. 1). The intake of sophisticated food was almost null.8
Baseline dietary data showed large differences in satu-
rated fat intake across worldwide cohorts. Intake of
saturated fat was low in southern European Mediterra-
nean cohorts and in Japan.9 Cereals and wine consump-
tion is typical in Italy; bread consumption was high in the
Yugoslavian cohorts apart from in Belgrade, with large
amounts of vegetables and fish in Dalmatia; olive oil and
fruit consumption was high in Greece; fish, rice, and soy
products were typical of the Japanese cohorts.10
It was observed that there were strong and significant
associations between saturated fat (as total energy intake
proportions) and coronary artery disease (CAD) incidence
or mortality. Moreover, there were high inverse relation-
ships between polyunsaturated/saturated fat and mono-
unsaturated/saturated fat ratios on one side and CAD
mortality on the other.11,12 In the Mediterranean areas,
the high monounsaturated/saturated fat ratios reflected
the extensive use of olive oil. Although individual satu-
rated fatty acids (FAs), overall fat and dietary cholesterol
intake were directly associated with CAD mortality, this
was not the case for oleic acid and polyunsaturated FAs.
On the other hand, carbohydrate intake was inversely and
significantly correlated with CAD rates. These results
were compatible with the causal hypothesis that diets
high in saturated fat intake – leading to high average
levels of serum cholesterol – were responsible for greater
CAD incidence and mortality rates across populations.
It was hypothesized that decreasing the consumption of
dairy products by half might be associated with a 20%© 2017 Italian Federation of Cadecline in CAD mortality over a 25-year period. A 25%
lower consumption of animal foods and a concomitant
increase of plant foods by 25% might be associated with a
32% decline in 25-year CAD mortality.12
A systematic evaluation of eating patterns was carried out
over a 25-year follow-up (starting with a testing sample of
people aged 45–64 years) in five cohorts (two in Finland,
one in the Netherlands, and two in Italy). The general
eating habits remained the same throughout the 25 years.
Saturated fat decreased by 3% of total energy in Finland
and by less than 1% in Italy.13
New research has confirmed and expanded the concept of
MedD and the results of the Seven Country Study.14,15
The European Prospective Investigation into Cancer and
Nutrition (EPIC) has provided important evidence,
based on analyses on large numbers of patients.16 MedD
proved protective on renal function, levels of serum uric
acid, weight control, metabolic syndrome, and on devel-
oping ischemic stroke.17–20 More recently, a study on the
MedD has stimulated important comparative procedures
between the a-priori and the a-posteriori approach for the
definition of dietary patterns.21 This research period has
enabled the concept of MedD to gradually take form and
its benefits, regarding low incidence, prevalence, and
mortality from CHD, have been expanded to other
CVDs, and all-causes mortality including cancer.22
The characteristics and virtues of the MedD were
recently accompanied by a declaration from United
Nations Educational, Scientific and Cultural Organiza-
tion, which classified the MedD as a ‘cultural heritage of
humanity’. It is however important to stress that there are
probably no longer populations homogeneous to the
MedD patterns, although within most populations it is
certainly possible to identify subgroups of people whose
eating habits, casually or deliberately, have enjoyed
better health and longevity, by adopting the traditional
Seven Countries Study Mediterranean Diet.rdiology. All rights reserved.
CE: Swati; JCM-D-17-00228; Total nos of Pages: 11;
JCM-D-17-00228
Mediterranean diet and cardiovascular diseases Mattioli et al. 3
T
a
b
le
1
T
h
e
e
ff
e
ct
s
o
f
M
e
d
it
e
rr
a
n
e
a
n
d
ie
t
o
n
p
e
ri
p
h
e
ra
l
a
rt
e
ry
d
is
e
a
se
:
th
e
o
ve
rv
ie
w
fr
o
m
lit
e
ra
tu
re
R
ef
er
en
ce
N
am
e
o
f
th
e
st
ud
y
T
yp
e
o
f
st
ud
y
D
es
ig
n
P
at
ie
nt
s
M
ai
n
re
su
lts
R
ui
z-
C
an
el
a
et
al
.3
1
P
R
E
D
IM
E
D
M
ul
tic
en
te
r,
ra
nd
o
m
iz
ed
,
p
rim
ar
y
p
re
ve
nt
io
n
tr
ia
l
R
an
d
o
m
iz
at
io
n
1
:1
:1
3
g
ro
up
s:
M
ed
D
þ
o
liv
e
o
il
(2
5
3
9
p
ts
);
M
ed
D
þ
nu
ts
(2
4
5
2
p
ts
);
co
nt
ro
ls
(2
4
4
4
p
ts
)
#6
6
%
P
A
D
in
ci
d
en
ce
[H
R
:
0
.3
4
(0
.2
0
–
0
.5
8
)]
in
M
ed
D
þ
o
liv
e
o
il
#5
0
%
P
A
D
in
ci
d
en
ce
[H
R
:
0
.5
0
(0
.3
0
–
0
.8
1
)]
in
M
ed
D
þ
nu
ts
N
N
T
¼
3
3
6
(9
5
%
C
I
2
6
9
–
5
6
6
)
fo
r
M
ed
D
þ
o
liv
e
o
il
N
N
T
¼
4
4
8
(9
5
%
C
I
3
1
6
–
1
5
3
6
)
fo
r
M
ed
D
þ
nu
ts
M
ar
tı´n
ez
-G
o
nz
a´l
ez
et
al
.3
4
P
R
E
D
IM
E
D
M
ul
tic
en
te
r,
ra
nd
o
m
iz
ed
,
p
rim
ar
y
p
re
ve
nt
io
n
tr
ia
l
R
an
d
o
m
iz
at
io
n
1
:1
:1
3
g
ro
up
s:
M
ed
D
þ
o
liv
e
o
il
(2
5
3
9
p
ts
);
M
ed
D
þ
nu
ts
(2
4
5
2
p
ts
);
co
nt
ro
ls
(2
4
4
4
p
ts
)
N
um
b
er
ex
p
ec
te
d
p
re
ve
nt
ed
P
A
D
ca
se
s:
1
0
ca
se
s
in
a
hy
p
o
th
et
ic
al
co
ho
rt
o
f
1
0
0
0
p
ts
C
ic
ca
ro
ne
et
al
.3
5
P
ro
sp
ec
tiv
e
co
ho
rt
st
ud
y
N
o
t
ra
nd
o
m
iz
ed
1
4
4
P
A
D
p
ts
2
8
8
ty
p
e
2
d
ia
b
et
es
p
ts
Lo
w
es
t
M
ed
D
sc
o
re
te
rt
ile
s:
-
2
.6
3
(d
ia
b
et
es
d
ur
at
io
n
<
1
0
ye
ar
s)
hi
g
he
r
ris
k
o
f
P
A
D
p
ro
g
re
ss
io
n
-
3
.9
-f
o
ld
(d
ia
b
et
es
d
ur
at
io
n
>
1
0
ye
ar
s)
hi
g
he
r
ris
k
o
f
P
A
D
p
ro
g
re
ss
io
n
-
5
.9
-f
o
ld
(h
yp
er
te
ns
iv
e)
hi
g
he
r
ris
k
o
f
P
A
D
p
ro
g
re
ss
io
n
H
o
ev
en
aa
r-
B
lo
m
et
al
.3
6
E
P
IC
-N
L
P
ro
sp
ec
tiv
e
co
ho
rt
st
ud
y
N
o
t
ra
nd
o
m
iz
ed
4
0
0
1
1
p
ts
#2
6
%
[H
R
:
0
.7
4
(9
5
%
C
I
0
.4
5
–
1
.2
1
)]
in
P
A
D
ris
k
in
hi
g
hl
y
ad
he
re
nt
to
M
ed
D
va
n
d
e
La
ar
et
al
.3
9
A
G
A
H
LS
O
b
se
rv
at
io
na
l
st
ud
y
N
o
t
ra
nd
o
m
iz
ed
1
9
6
p
ts
In
cr
ea
se
d
ar
te
ria
l
st
iff
ne
ss
in
le
ss
ad
he
re
nt
to
M
ed
D
G
ar
d
en
er
et
al
.4
0
N
O
M
A
S
O
b
se
rv
at
io
na
l
st
ud
y
N
o
t
ra
nd
o
m
iz
ed
1
3
7
4
p
ts
0
.0
4
9
m
m
re
d
uc
tio
n
in
p
la
q
ue
th
ic
kn
es
s
ea
ch
1
-p
o
in
t
in
cr
ea
se
in
M
ed
D
sc
o
re
,
P
¼
0
.0
3
0
.3
7
1
m
m
2
re
d
uc
tio
n
in
p
la
q
ue
ar
ea
ea
ch
1
-p
o
in
t
in
cr
ea
se
in
M
ed
D
sc
o
re
,
P
¼
0
.0
3
S
al
a-
V
ila
et
al
.4
1
P
R
E
D
IM
E
D
su
b
co
ho
rt
M
ul
tic
en
te
r,
ra
nd
o
m
iz
ed
,
p
rim
ar
y
p
re
ve
nt
io
n
tr
ia
l
R
an
d
o
m
iz
at
io
n
1
:1
:1
1
7
5
p
ts
M
ed
D
g
ro
up
þ
nu
ts
vs
.
co
nt
ro
ls
:
#0
.0
8
4
m
m
(
0
.1
5
8
to
0
.0
1
0
m
m
,
P
¼
0
.0
2
4
)
c-
IM
T
#0
.0
3
0
m
m
(
0
.1
5
3
to
0
.0
9
3
m
m
,
P
¼
0
.0
3
4
)
m
ax
im
um
in
te
rn
al
c-
IM
T
A
G
A
H
LS
,A
m
st
er
d
am
G
ro
w
th
an
d
H
ea
lth
Lo
ng
itu
d
in
al
S
tu
d
y;
C
I,
co
nfi
d
en
tia
li
nd
ex
;c
-IM
T
,c
ar
o
tid
in
tim
a
–
m
ed
ia
th
ic
kn
es
s;
E
P
IC
-N
L,
E
ur
o
p
ea
n
P
ro
sp
ec
tiv
e
In
ve
st
ig
at
io
n
in
to
C
an
ce
r
an
d
N
ut
rit
io
n
–
N
L
(D
ut
ch
co
nt
rib
ut
io
n)
;
H
R
,
ha
za
rd
ra
tio
;
M
ed
D
,
M
ed
ite
rr
an
ea
n
d
ie
t;
N
N
T
,
nu
m
b
er
-n
ee
d
-t
o
-t
re
at
;
N
O
M
A
S
,
N
o
rt
he
rn
M
an
ha
tt
an
S
tu
d
y;
P
A
D
,
p
er
ip
he
ra
l
ar
te
ry
d
is
ea
se
s;
P
R
E
D
IM
E
D
,
P
R
E
ve
nc
io´
n
co
n
D
Ie
ta
M
E
D
ite
rr
a´n
ea
;
p
ts
,
p
at
ie
nt
s.
AQ1Prevalence of unhealthy lifestyle habits
With few exceptions, age-standardized mortality rates
from CVD have fallen in European countries from
2000 to 2010; nonetheless, CVD still caused 1.48 million
premature deaths and 37% of all deaths in 2010.2 It has
been estimated that 24% of the total costs for CVD in
Europe are due to productivity losses.23
Improving cardiovascular health is a strategic goal in public
health.1,24,25 The contribution of unhealthy lifestyle
behaviors to the development of CVD in high-income
and middle-income countries is unquestionable.5 Sustain-
able health policies are needed to promote healthy lifestyle
behaviors including not smoking, having a healthy dietary
pattern and a normal BMI, abstaining from excessive
alcohol use, and maintaining regular physical activity.3,6,23
Smoking cessation is associated with decreased risk
for CVD.4 Regular physical activity is associated with
decreased risk for CVD and cardiovascular mortality.4 A
moderate-intensity physical activity for at least 30 min a
day five times a week is recommended.3 Only 27% of adult
European citizens meet these activity recommendations.23
Dietary habits influence CVD risk.3 In the 2013 WHO
Ministerial Conference on Nutrition and NonCommunic-
able Diseases, it was recognized that ‘a healthy diet can
contribute to achieving the global targets on NCDs
adopted by the Sixty-sixth World Health Assembly, includ-
ing achieving a 25% relative reduction in premature mor-
tality from NonCommunicable Diseases by 2025’.26 Core
components of a healthy diet include limiting intakes of
saturated and trans fats, carbohydrate, alcohol, and sodium
and increasing intakes of fruit, vegetables, and dietary
fibers. The MedD meets these healthy diet requirements.
The cost-effectiveness analysis performed by Abdullah
et al.27 confirms this statement. The analysis estimates that
reduction in costs, consequent to an improve management
of CVD events, will be of $ 41.9 million in Canada and $1.0
billion in the United States in the ‘worst case’ scenario
represented by a 5% of the population switching to MedD
and having a 10% reduction in CVD.27
Mediterranean diet and peripheral artery
disease
Peripheral artery disease (PAD) is one of the most impor-
tant manifestations of atherosclerotic disease.28 The overall
prevalence of the disease, assessed in several epidemiolog-
ical studies, ranges from 3 to 10%, being incremented to
15–20% over the age of 70.29 The cardiovascular risk
factors associated with an increased incidence of PAD
are diabetes mellitus and cigarette smoking, followed by
arterial hypertension, obesity, and dyslipidemia. In many
patients with PAD, these risk factors are simultaneously
present, determining the metabolic syndrome.30
MedD can dramatically improve prognosis, clinical
course of PAD, and reduction in negative outcomes
(Table 1).© 2017 Italian Federation of Cardiology. All rights reserved.
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December 2010 in Spain, tested the effect of the MedD
enriched with olive oil or dry nuts in 7477 participants with
type 2 diabetes mellitus or at least three cardiovascular risk
factors, aged 55–80 years and without baseline overt
clinical PAD or CVD. PREDIMED was a primary pre-
vention trial. Authors observed a 66% reduction in PAD
incidence [hazard ratio: 0.34 (95% confidential index 0.20–
0.58)] in patients undergone MedD plus extra-virgin olive
oil and a 50% reduction in PAD incidence [hazard ratio:
0.50 (95% confidential index 0.30–0.81)] in the group
treated with MedD plus nuts, compared with the control
group.31 All results were obtained after adjusting for con-
founding factors. Furthermore, the number-need-to-treat
(NNT) was 336 (95% confidential index 269–566) for the
MedD plus extra-virgin olive oil group and 448 (95%
confidential index 316–1536) for the MedD plus nuts
group. Although these numbers are far from those of well
established pharmacological treatments (i.e. NNT for
PAD primary prevention with statins: from 24 to 4232;
NNT for PAD primary prevention with ACE-inhibitors: 7
(95% confidential index 5–12)33), they suggest an impor-
tant role of eating habits on PAD progression. A further
analysis revealed a number of expected prevented PAD
cases of 10 out of 1000 patients.34
Ciccarone et al.35 showed the protective role of the MedD
in counteracting PAD development in patients with type
2 diabetes mellitus. They observed that the higher the
MedD score – representing greater adherence to MedD
– the lower the risk of PAD. Although diabetes duration
and hypertensive condition can negatively impact PAD
occurrence, a high MedD score is associated with a
decrease progression of the disease. Patients in the lowest
score tertile showed a 2.63 (diabetes duration <10 years)
and 3.9-fold (diabetes duration >10 years) higher risk of
PAD progression as compared with their higher counter-
parts.35 Such differences dramatically increased when
considering hypertensive condition: hypertensive indi-
viduals who poorly followed MedD displayed a 5.9-fold
higher risk of PAD than those adhering to MedD.35
The EPIC-NL cohort study supported the previous
findings.36 The Authors prospectively followed up
40 011 men and women aged 20–70 years. They were
enrolled between 1993 and 1997 and followed for 10–
15 years (mean 11.8 years).36 The study was design for
investigating the influence of MedD on cardiovascular
outcomes occurrence. By splitting results, the authors
observed a 26% [hazard ratio: 0.74 (95% confidential
index 0.45–1.21), after correction for confounding fac-
tors] reduction in PAD occurrence in patients highly
adherent to MedD, as assessed by means of the modified
Mediterranean diet score.36
The reasons for such improvements in the overall car-
diovascular risk burden of individuals prone to or suffer-
ing from PAD are not fully understood. Klonizakis et al.37© 2017 Italian Federation of Cashowed that vascular function may benefit from MedD.
The lower limb vascular endothelial cutaneous vascular
conductance improved in patients who had undergone
MedD even at 1-year follow-up.37 Although the study
was not set for PAD patients – the authors enrolled 20
healthy individuals – it provides insights on possible
mechanisms explaining the positive effects of MedD
in such patients.
The reasons behind the improvement of disease and the
prevention of PAD in patients following MedD regimen
can be related to the positive effect on arterial walls.38
The Amsterdam Growth and Health Longitudinal Study
compared longitudinal levels of adherence with MedD,
during adolescence and adulthood (two to eight repeated
measures obtained between the ages of 13 and 36 years)
between individuals, with different levels of arterial
stiffness in adulthood.39 The study population included
373 (196 women) apparently healthy adults who under-
went carotid, brachial, and femoral arteries ultrasound
evaluations at 36 years of age. After adjustments for
confounders, individuals with stiffer carotid arteries
had lower adherence scores and were less likely to have
adhered to this dietary pattern during the preceding
24 years compared with those with less stiff arteries.
Therefore, MedD may prevent arterial stiffness in adult-
hood, and consequently the development of PAD.39
MedD can also influence the peripheral atherosclerotic
burden. Gardener et al.40 outlined the positive effect of
MedD on carotid plaque thickness and median plaque
area progression: the 1374 patients enrolled in the North-
ern Manhattan Study showed that the increase in 1 point
of MedD score was able to significantly reduce the 75th
percentile of plaque thickness (0.049 mm, P¼ 0.03,
after adjusting for confounding factors) and the median
of plaque area (0.371 mm2, P¼ 0.03).40
A substudy from PREDIMED41 also revealed a relative
regression of internal carotid intima–media thickness (c-
IMT) in MedD group plus nuts [0.084 mm (0.158 to
0.010 mm); P¼ 0.024 vs. control], as well as maximum
internal c-IMT [0.030 mm (0.153 to 0.093 mm);
P¼ 0.034], even after adjusting for confounding factors.
Although the pathophysiological mechanisms are not yet
clarified, several studies show the effectiveness of the
MedD in preventing the development of PAD especially
in young patients.42
Mediterranean diet in chronic coronary artery
disease patients
CAD is the most common cause of death in developed
countries, responsible for about one out of five deaths.
Chronic stable angina (CSA) is the first presentation of
CAD in about 50% of patients, affecting about 17 million
people in the United States.43 Nutrition plays an increas-
ingly significant role for secondary prevention of cardio-
vascular events in CSA.44–47rdiology. All rights reserved.
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© 2017 Italian Federation of CMedD can further improve the outcomes of these
patients (Table 2). The PREDIMED study22 on primary
prevention of adverse outcomes revealed a significant
reduction in the primary composite endpoint of the study
[acute myocardial infarction (MI), stroke, or death from
cardiovascular causes]: the use of MedD plus olive oil
(hazard ratio: 0.70, 95% confidential index 0.53–0.91,
P¼ 0.009) and MedD plus nuts (hazard ratio: 0.70,
95% confidential index 0.53–0.94, P¼ 0.02) both
decreased the incidence of the composite endpoint of
30%. Nevertheless, when splitting the single endpoints,
they found that previous results were triggered by the
significant reduction in stroke occurrence rather than
acute MI of death from cardiovascular causes. Similar
results came from the analyses of the Northern Manhat-
tan Study48: higher adherence to MedD did not signifi-
cantly reduce the occurrence of MI (hazard ratio: 0.65,
95% confidential index 0.38–1.12, P¼ 0.27). Neverthe-
less, the EPIC-NL cohort study36 in apparently healthy
individuals outlined the significant reduction in the
occurrence of MI after adjusting for confounders in
patients showing higher adherence to MedD (hazard
ratio: 0.86, 95% confidential index 0.79–0.93).
The cardiovascular Spanish section of the EPIC study – a
prospective European study involving healthy individuals
– pointed out a further 40% reduction in the risk of CAD
occurrence in the patients highly adherent to MedD
(hazard ratio: 0.60, 95% confidential index 0.47–0.77,
P< 0.001), even after the adjustment for confounders.49,50
The Lyon Diet Heart Study provided information about
the role of MedD in the secondary prevention of adverse
outcomes after acute MI.51,52 This was a randomized,
single-blind secondary prevention trial in patients ana-
lyzing the incidence of three composite outcomes: MI
plus cardiovascular death (composite outcome 1); MI plus
cardiovascular death plus major secondary events (unsta-
ble angina occurrence, overt heart failure, stroke, or
pulmonary or peripheral embolism) (composite outcome
2); the preceding plus minor events requiring hospital
admission, including recurrent stable angina, postangio-
plasty restenosis, surgical or medical myocardial revascu-
larization, and thrombophlebitis (composite outcome 3).
MedD was able to significantly reduce the occurrence
of all-cause and cardiovascular death (P< 0.05). All the
three composite outcomes were significantly reduced
(P¼ 0.0001 for composite outcome 1 and composite
outcome 2 and P¼ 0.0002 according to composite out-
come 3). At multivariate proportional-hazards analyses,
MedD was able to reduce the occurrence of composite
outcome 1 of 72% [conditional risk ratios (CRRs) 0.28,
0.15–0.53, P< 0.05], composite outcome 2 of 67% (CRR
0.33, 0.21–0.52, P< 0.05), and composite outcome 3 of
47% (CCR 0.53, 0.38–0.74, P< 0.05).51
A subanalysis53 of the GISSI-Prevenzione study involv-
ing patients surviving recent (3 months or less) MIardiology. All rights reserved.
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e.pointed out a 15% (95% confidential index 12–18%)
reduction in the occurrence of mortality each unit
increase in the MedD score. The authors calculated a
14% reduction in the overall risk of mortality after 6.5-
year follow-up.53 Although this subanalysis did not reveal
the incidence of further coronary events, data on mortal-
ity are fundamental to consider the overall impact of
MedD on health.
The prospective analysis from Iestra et al.54 outlined the
reduction in mortality risk (hazard ratio: 0.75; 95% confi-
dential index 0.57–0.97) in patients following MedD and
recently suffering from MI.54
The hypotheses accounting for the positive effects of
MedD on cardiovascular outcomes of patients suffering
from CAD are different, but not conclusive. A subanalysis
from PREDIMED study pointed out the reduction in
CD40 expression on monocytes surface (34%, P¼ 0.03),
and a further decrease in C-reactive protein and IL-6 in
both MedD groups (plus olive oil and plus nuts).55
Accordingly, the expression of adhesion molecules such
as soluble intracellular Cell Adhesion Molecule and P-
selectin was significantly reduced in both groups as
compared with controls (P¼ 0.04).55 All of these molec-
ular changes suggest a protection of atherosclerotic pla-
ques from instability and/or negative progression related
to the adherence to MedD, which was persistent even at
12-month follow-up. The 5-year follow-up of this group
of patients confirmed the statistical significant reduction
in inflammatory markers56: IL-6 and IL-8, monocyte
chemotactic protein-1, TNF-a, adhesion molecules were
significantly reduced following MedD treatment, acting
as a possible mechanism for cardiovascular
risk prevention.
Therefore, as confirmed by literature, MedD may play a
crucial role in primary and secondary prevention of
CADs.57
Mediterranean diet in patients with chronic
heart failure
Despite significant advances in pharmacological and non-
pharmacological therapy, heart failure continues to have
high morbidity and mortality and its prevalence is
increasing in most regions of the world.58,59 There is
consequently an evident need for novel therapeutic
approaches. Nutritional interventions appear to be par-
ticularly attractive because they could work additively
with established therapies without exerting negative
hemodynamic effects.
Healthy dietary patterns in general, including some
components of the MedD, have been associated with
lower incidence of heart failure in some observational
studies (Table 3).60–62 Recently, Tektonidis et al.63 in a
prospective study that included 37 308 men from Sweden
free from CVD at baseline, firstly demonstrated that high
adherence to MedD (assessed by a MedD score) was© 2017 Italian Federation of Cardiology. All rights reserved.
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Mediterranean diet and cardiovascular diseases Mattioli et al. 7associated with a 31% [relative risk (RR): 0.69, 95%
confidential index 0.57–0.83; P for trend <0.001] reduc-
tion in risk of heart failure development over a median
follow-up time of 10.9 years. Moreover, mortality related
to heart failure was significantly reduced in patients
highly adherent to MedD (RR: 0.55, 95% confidential
index 0.31–0.98; P for trend¼ 0.007), after adjusting for
confounding factors.63
Data from ‘PREDIMED’ did not show reduction in heart
failure occurrence in the population following MedD
combined with extra-virgin oil or nuts as compared with
controls.64 Despite the strict adherence to the dietetic
regimens, there was a similar incidence of heart failure
among the three groups at 4.8-year median follow-up.
Heart failure was a secondary outcome of the PRE-
DIMED study and, probably, was underpowered for
the final analysis. Authors suggested a further controlled
trial designed ad hoc for this purpose. Despite this lack of
difference among groups, Fito´ et al.65 observed a signifi-
cant reduction in plasma N-terminal pro-brain natriuretic
peptide in MedD groups as compared with controls,
whereas no variation was observed in urinary albumin
or albumin/creatinine ratio.
The EPIC-Potsdam substudy confirmed the PRE-
DIMED results66: among the 9225 men and 14 783
women enrolled in the study, there was no relationship
between heart failure occurrence and adherence to
MedD. Although the gross analysis revealed a significant
reduction in heart failure occurrence, the multivariate
regression analysis did not confirm the results (highest
adherence group: hazard ratio: 0.66, 95% confidential
index 0.41–1.08, P for trend 0.10).66 Further analysis
should be considered in the adoption of MedD in the
setting of strategies for primary prevention of heart
failure.
An interesting point of view about this matter comes from
the analysis of the Multi-Ethnic Study of Atherosclerosis
study.67 The authors applied the MedD score for the
evaluation of these patients whose cardiac function and
morphology were also combined for the final evaluation.
The higher the MedD score the higher the left ventricle
(LV) mass and volume, as well as stroke volume and LV
ejection fraction. This cross-sectional association revealed
the skills of MedD to enhance the structure and the
function of the LV in apparently healthy individuals.
Different results come from the analysis of secondary
prevention studies. A subanalysis from the Women’s
Health Initiative study involved about 3215 participants
who experienced hospitalization for heart failure.68
These women were followed up for a median time of
4.6 years, and their daily dietary patterns were also
periodically evaluated. Patients showing higher MedD
adherence showed a trend for reduced mortality for heart
failure (hazard ratio: 0.85, 95% confidential index 0.70–
1.02, P¼ 0.08) after adjusting for several confounding© 2017 Italian Federation of Cfactors.68 A good adherence to MedD after acute coronary
syndrome (ACS) was significantly associated with
reduced incidence of LV dysfunction during hospitaliza-
tion, whereas higher MedD score showed a trend toward
reduced negative LV remodeling within 3 months after
the acute event.69
Significantly, Chrysohoou et al.70 observed that greater
adherence to MedD was slightly associated with better
LV filling pressure and better biventricular systolic func-
tion in chronic heart failure patients with LV ejection
fraction less than 40%. In particular, after adjusting for
potential confounding factors (e.g. age, sex, physical
inactivity, smoking habits, obesity, history of hyperten-
sion, hypercholesterolemia and diabetes mellitus, ejec-
tion fraction, and years of heart failure), log E wave/A
wave ratio was inversely associated with the MedD
score.70 Furthermore, aliment-specific analysis revealed
the potential beneficial effect of vegetables, fish, and
olive oil on LV and right ventricular systolic and diastolic
indices, suggesting a further nonpharmacological thera-
peutic strategy in these patients.70
In conclusion, even though evidence is not conclusive,
MedD may positively impact on reverse remodeling in
heart failure patients or in patients likely to develop
heart failure.
Mediterranean diet effects on arrhythmias
and sudden cardiac death
The effects of MedD on arrhythmias prevention and/or
sudden cardiac death (SCD) are poorly established
(Table 4).71 The GISSI-Prevenzione Investigators dem-
onstrated that early administration of v-3 poly-unsatured
fatty acids (PUFA) supplementation (a well established
component of MedD) in patients recently suffering from
ACS can reduce the occurrence of SCD.72 The authors
suggested a possible antiarrhythmic role of v-3 PUFA on
heart as the key role for SCD prevention.
The Women’s Health Initiative substudy involved 93 122
postmenopausal women who were evaluated for the
MedD and, in parallel, for the occurrence of SCD.73
The research found a total of 237 SCD. The statistical
analyses and the corresponding adjustment for confound-
ing factors did not outline the superiority of higher
adherence to MedD in prevention of SCD. Nevertheless,
women in the highest quintile showed a not significant
36% reduction (highest to lowest quintile hazard ratio:
0.64, 95% confidential index 0.43–0.94, P¼ 0.21) in SCD
reduction as compared with those poorly adherent to
MedD.73 The Isfahan Cohort Study considered a com-
posite endpoint of fatal MI, fatal stroke (i.e. death from
cerebrovascular disease) and SCD; it demonstrated that
MedD was effectively able to strongly reduce the occur-
rence of the primary endpoint (hazard ratio: 0.42, 95%
confidential index 0.19–0.96, P for trend¼ 0.02 after
adjusting for confounding factors) more than otherardiology. All rights reserved.
CE: Swati; JCM-D-17-00228; Total nos of Pages: 11;
JCM-D-17-00228
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Table 5 Mediterranean diet and cardiovascular disease: what is
known and potential beneficial mechanisms related to high intake
of fruit and vegetables, strongly present in Mediterranean diet
MedD and cardiovascular disease
MedD reduces mortality for cardiovascular disease83
MedD significantly reduced the risk of metabolic syndrome and protected
against risk factors such as waist circumference, lipids, glucose, and blood
pressure in primary prevention20
MedD provided a more robust reduction in cardiovascular disease risk factors
and inflammatory markers55,56
Nutrition plays an increasingly significant role for secondary prevention of CV
events in CSA47
MedD have been associated with lower incidence of HF in some observational
studies60–62
Potential beneficial mechanisms related to high intake of fruit and vegetables,
strongly present in MedD
Antioxidant properties of fruit and vegetables84
Well known health benefits of high flavonol intake85
Potential increase in nitric oxide species86
Concomitant weight loss associated with diets high in fruits and vegetables.
Reduction of blood pressure87
Reduction of inflammatory markers
CSA, chronic stable angina; CV, cardiovascular; HF, heart failure; MedD, Medi-
terranean diet.
© 2017 Italian Federation of Cadietary patterns (i.e. Western diet, animal fat diet, and
fast food diet).74
Data on the relationship between MedD and atrial fibril-
lation occurrence/recurrences are controversial (Table 4).
The changes in nutritional habits might reduce the
occurrence of arrhythmias.75–77 According to MedD, a
post-hoc analysis of the PREDIMED study revealed a
38% (hazard ratio: 0.62; 95% confidential index 0.45–0.85
vs. control group) reduction in atrial fibrillation occur-
rence when adopting MedD plus olive oil. These data
were obtained after adjusting for confounding factors.77
Mattioli et al.76 confirmed the lower incidence of atrial
fibrillation in patients following MedD as compared with
controls. The interesting result of their research was
related to the higher probability of sinus rhythm conver-
sion in patients highly adherent to MedD. They observed
a 90% (odds ratio 1.90, 95% confidential index 1.58–2.81,
P¼ 0.001) probability of fast rhythm conversion in
patients declaring high MedD score.76 An interesting
insight from Mattioli et al.76 was related to a possible
role of antioxidant properties of MedD on atrial fibrilla-
tion expression. Pastori et al.78,79 confirmed such patho-
genetic hypothesis. This group observed that higher
adherent atrial fibrillation patients showed reduced
levels of soluble NADPH oxidase 2-derived peptide
and F2-isoprostanes,78 and increased levels of glutathi-
one peroxidase 3.79 These results confirmed the anti-
oxidant properties of MedD in atrial fibrillation, thus
suggesting positive effects for the conversion or reduction
of its occurrence/recurrence.
Furthermore, MedD can prevent major cardiovascular
events related to atrial fibrillation.78,80 Beyond antioxi-
dant properties, the demonstration of stable time-in-
therapeutic range for warfarin-treated patients80,81 as well
as the reduction in thromboxane A2 production (i.e.rdiology. All rights reserved.
CE: Swati; JCM-D-17-00228; Total nos of Pages: 11;
JCM-D-17-00228
Mediterranean diet and cardiovascular diseases Mattioli et al. 9reduced tendency to platelets to aggregate)82 accounts for
the reduced rate of atrial fibrillation-related adverse events.
Although confirmatory, structured, randomized trials
should be adopted for these issues, the scientific back-
ground seems to favor the MedD in possible, positive
influence on outcomes of SCD and/or atrial fibrillation
patients.
Conclusion
The MedD is a reliable weapon against CVD progression.
It positively affects endothelial function, arterial stiff-
ness, and cardiac remodeling (Fig. 1 and Table 5).83–87
The consequence is a reduction in the occurrence of
PADs, improvements in the outcomes of CADs and heart
failure (Fig. 1 and Table 5).83–87 Therefore, the adoption
of MedD can reduce the CVD manifestations and con-
sequences, promoting healthy lifestyle and best manage-
ment of body care.
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